JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1527-1534

  Liu, Zhe ^a   Du, Ruixia ^a   Long, Jin ^a   Dong, Anbing ^a   Fan, Jianpeng ^a   Guo, Kejian ^a   Xu, Yuanhong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

EGF; Epithelial to mesenchymal; JDP2; Pancreatic cancer; TGF 1

Indexed keywords

EPIDERMAL GROWTH FACTOR; JUN DIMERIZATION PROTEIN 2; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

EID: 84868099750     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0404-5     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56:106-30.
2. Huang TC, Kar S, Javle M. Personalized therapy for pancreatic cancer: myth or reality in 2010? J Gastrointest Oncol. 2010;1:24-33.
3. Kotowski A, Ma WW. Emerging therapies in pancreas cancer. J Gastrointest Oncol. 2011;2:93-103.
4. Xiao DK, He JX. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2:154-9.
5. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-54.
6. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277-9.
7. Xie L, Law BK, Chytil AM, et al. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia (New York). 2004;6:603-10.
8. Davies M, Robinson M, Smith E, et al. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem. 2005;95:918-31.
9. Aronheim A, Zandi E, Hennemann H, et al. Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol. 1997;17:3094-102.
10. Jin C, Ugai H, Song J, et al. Identification of mouse Jun dimerization protein 2 as a novel repressor of ATF-2. FEBS Lett. 2001;489:34-41.
11. Kimura M. IRF2-binding protein-1 is a JDP2 ubiquitin ligase and an inhibitor of ATF2-dependent transcription. FEBS Lett. 2008;7:317-24.
12. Ostrovsky O, Bengal E, Aronheim A. Induction of terminal differentiation by the c-Jun dimerization protein JDP2 in C2 myoblasts and rhabdomyosarcoma cells. J Biol Chem. 2002;277:40043-54.
13. Piu F, Aronheim A, Katz S, et al. AP-1 repressor protein JDP-2: inhibition of UV-mediated apoptosis through p53 down-regulation. Mol Cell Biol. 2001;21:3012-24.
14. Bitton-Worms K, Pikarsky E, Aronheim A. The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Mol Cancer. 2010;9:54.
15. Nakade K, Pan J, Yamasaki T, et al. JDP2 (Jun dimerization protein 2)-deficient mouse embryonic fibroblasts are resistant to replicative senescence. J Biol Chem. 2009;284:10808-17.
16. Jin C, Kato K, Chimura T, et al. Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Nat Struct Mol Biol. 2006;13:331-8.
17. Nishioka R, Itoh S, Gui T, et al. SNAIL induces epithelial-to-mesenchymal transition in a human pancreatic cancer cell line (BxPC3) and promotes distant metastasis and invasiveness in vivo. Exp Mol Pathol. 2010;89:149-57.
18. Cho SG, Yi Z, Pang X, et al. Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res. 2009;69:7062-70.
19. Ellenrieder V, Hendler SF, Boeck W, et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001;61:4222-8.
20. Heinrich R, Livne E, Ben-Izhak O, et al. The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene. J Biol Chem. 2004;279:5708-15.
21. Jin C, Li H, Murata T, et al. JDP2, a repressor of AP-1, recruits an HDAC3 complex to inhibit the retinoic acid-induced differentiation of F9 cells. Mol Cell Biol. 2006;22:4815-26.
22. Weiss G, Rasmussen S, Nielsen Fink L. Bifidobacterium bifidum actively changes the gene expression profile induced by Lactobacillus acidophilus in murine dendritic cells. PLoS One. 2010;5:e11065.
23. Wang P, Chen Z, Meng Z, et al. Dual role of Ski in pancreatic cancer cells: tumor-promoting versus metastasis-suppressive function. Carcinogenesis. 2009;30:1497-506.
24. Yasutome M, Gunn J, Korc M. Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis. Clin Exp Metastasis. 2005;22:461-73.
25. Shintani Y, Hollingsworth MA, Wheelock MJ. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH2-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res. 2006;66:11745-53.
26. Pan J, Yang M. The role of epithelial-mesenchymal transition in pancreatic cancer. J Gastrointest Oncol. 2011;2:151-6.
27. Thiery JP, Acloque H, Huang RY. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-90.
28. Hsueh C. Pancreatic cancer: current standards, research updates and future directions. J Gastrointest Oncol. 2011;2:123-5.
29. Kikuta K, Masamune A, Watanabe T. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun. 2010;403:380-4.
30. Onoue T, Uchida D, Begum NM. Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol. 2006;29:1133-8.
31. Yuanhong X, Feng X, Qingchang L, et al. Downregulation of AP-1 repressor JDP2 is associated with tumor metastasis and poor prognosis in patients with pancreatic carcinoma. Int J Biol Markers. 2010;25:136-40.
32. Lerdrup M, Holmberg C, Dietrich N, et al. Depletion of the AP-1 repressor JDP2 induces cell death similar to apoptosis. Biochim Biophys Acta. 2005;1745:29-37.
33. Pan J, Nakade K, Huang YC, et al. Suppression of cell-cycle progression by Jun dimerization protein-2 (JDP2) involves downregulation of cyclin-A2. Oncogene. 2010;29:6245-56.
34. Benbrook DM, Jones NC. Heterodimer formation between CREB and JUN proteins. Oncogene. 1990;5:295-302.
35. Jensen K, Afroze S, Munshi MK, et al. Mechanisms for nicotine in the development and progression of gastrointestinal cancers. Transl Gastrointest Cancer. 2012;1:81-7.
36. Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 2003;63:8103-7.
37. Lee SH, Bahn JH, Whitlock NC, Baek SJ. Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene. 2010;29(37):5182-92.